The April 29th story refers to a 9th paragraph change in marketing mark.

By Dietrich Knauth

(Reuters] – A U.S. appeals court judge appeared hesitant Friday to restore a legal defense that would have protected members of Purdue Pharma’s Sackler family from suits related to OxyContin. This was a critical step in the company’s eventual bankruptcy.

Oral arguments were heard by a panel of three judges from the 2nd U.S. Circuit Court of Appeals was able to examine the boundaries of bankruptcy judges’ power to help non-bankrupt people like wealthy Sacklers.

A judge called the court’s past decisions “a weak ship” that it could build upon, and another did not give much weight to Purdue’s claim that Sackler protections were essential to fund opioid settlements.

Judge Jon Newman said, “Please do not shoot yourself in self-deprecating by claiming it is the Sacklers who make this plan legal.”

Purdue requires the court’s approval to restore the legal protection in order to execute its bankruptcy exit plan.

In return for legal protection, the Sacklers will contribute $6 billion to the plan. This money will be used to settle thousands against the company over its alleged involvement in the nationwide opioid crisis. Marshall Huebner from Purdue stated that Purdue without the participation of the Sacklers in the settlements would not be able get money for victims of opioid overdoses or programs to support state health.

The Office of the U.S. The legal shield was not renewed by Trustee (an arm of Department of Justice)

Attorney Michael Shih stated that the Sacklers shouldn’t be allowed to take advantage of bankruptcy protections, even if they file for bankruptcy.

Many lawsuits have been filed against Purdue and OxyContin for promoting the addictive pain medication. This has led to a U.S. epidemic of opioid overdoses that has resulted in some 500,000 deaths, according U.S. statistics. Purdue filed for bankruptcy in 2019 because of the litigation.

Although the Sacklers expressed their regret at OxyContin’s involvement in the crisis, they maintained that OxyContin was legal and necessary.

Purdue agreed to a settlement in bankruptcy for opioid claims. However, that agreement was rescinded by a federal judge who ruled that Connecticut-based Purdue could not wipe out lawsuits against non-bankrupt owners.

Purdue and its shareholders revised the terms for the opioid settlement, adding $1 billion from Sacklers. The total Sackler contribution was $6 billion. This ended any objections from the U.S. Trustee opposes legal barriers like these.

Non-debtor release, a legal protection, has been controversial and divided U.S. bankruptcy court courts.

The judges questioned Purdue as well as the U.S. Both the trustee and Purdue were unable to locate a section of bankruptcy law which supported their respective positions.

Purdue claimed that releases of nondebtors were not prohibited and cited past cases where they had been approved. According to the Trustee they weren’t allowed and bankruptcy courts are not permitted to exceed their authority for settling bankrupt company and individual debts.

Company pled guilty in 2007 to drug-related criminal charges.